From: Use of prescription medicines in Australian women of child-bearing age
Therapeutic group | Category A | Category B1 | Category B2 | Category B3 | Category C | Category D |
---|---|---|---|---|---|---|
Psycho-analeptics (NW : 42095) (ND : 245976) | Reboxetine (0.6 %) | Desvenlafaxine (16.2 %) | Duloxetine (9.5 %) | Sertraline (14.2 %) | Paroxetine (3.1 %) (N = 6574 dispenses) | |
Venlafaxine (13.3 %) | Mirtazapine (6.4 %) | Escitalopram (14.0 %) | ||||
Methylphenidate (1.3 %) | Dexamphetamine (1.1 %) | Fluoxetine (8.8 %) | ||||
Moclobemide (0.3 %) | Amitriptyline (7.0 %) | |||||
Citalopram (5.5 %) | ||||||
Fluvoxamine (2.0 %) | ||||||
Dothiepin (0.7 %) | ||||||
Doxepin (0.4 %) | ||||||
Clomipramine (0.3 %) | ||||||
Nortriptyline (0.3 %) | ||||||
Imipramine (0.2 %) | ||||||
Anti-bacterials for systemic use (NW: 106522) (ND: 178481) | Amoxycillin (26.0 %) | Amoxycillin with Clavulanic acid (17.0 %) | Dicloxacillin (1.5 %) | Trimethoprim (5.5 %) | Trimethoprim with sulphamethoxazole (1.4 %) | Doxycycline (6.4 %) (N = 12651) |
Cefalexin (22.5 %) | Roxithromycin (8.4 %) | Clarithromycin (4.0 %) | Minocycline (1.3 %) (N = 3103) | |||
Phenoxymethylpenicillin (5.1 %) | Flucloxacillin (3.6 %) | Ciprofloxacin (0.3 %) | ||||
Erythromycin (4.2 %) | Cefaclor (2.5 %) | Norfloxacin (0.3 %) | ||||
Clindamycin (1.2 %) | Azithromycin (1.9 %) | |||||
Nitrofurantoin (0.5 %) | Cefuroxime (0.4 %) | |||||
Hexamine (0.3 %) | ||||||
Analgesics (NW: 31705) (ND: 115460) | Codeine with paracetamol (53.2 %) | Rizatriptan (2.3 %) | Sumatriptan (3.3 %) | Oxycodone (17.5 %) | ||
Paracetamol (11.1 %) | Pizotifen (1.9 %) | Zolmitriptan (0.4 %) | Tramadol (13.5 %) | |||
Eletriptan (1.1 %) | Naratriptan (0.3 %) | Oxycodone comb. (2.3 %) | ||||
Buprenorphine (1.7 %) | ||||||
Fentanyl (1.1 %) | ||||||
Morphine (0.8 %) | ||||||
Hydromorphone (0.4 %) | ||||||
Psycholeptics (NW: 20157) (ND:111528) | Diazepam (37.2 %) | Lithium (3.0 %) (N = 1978) | ||||
Quetiapine (19.8 %) | ||||||
Temazepam (22.2 %) | ||||||
Prochlorperazine (15.7 %) | ||||||
Olanzapine (8.0 %) | ||||||
Oxazepam (7.3 %) | ||||||
Alprazolam (4.9 %) | ||||||
Risperidone (3.6 %) | ||||||
Aripiprazole (3.3 %) | ||||||
Nitrazepam (2.1 %) | ||||||
Paliperidone (1.5 %) | ||||||
Chlorpromazine (1.1 %) | ||||||
Asenapine (1.0 %) | ||||||
Amisulpride (0.9 %) | ||||||
Ziprasidone (0.9 %) | ||||||
Pericyazine (0.9 %) | ||||||
Clozapine (0.7 %) | ||||||
Zuclopenthixol (0.5 %) | ||||||
Drugs for obstructive airway diseases (NW: 34757) (ND: 88275) | Salbutamol (30.9 %) | Tiotropium (1.1 %) | Fluticasone with salmeterol (33.9 %) | |||
Budesonide (2.1 %) | Ipratropium (1.1 %) | Budesonide with eformoterol (26.0 %) | ||||
Terbutaline (1.4 %) | Nedocromil (1.1 %) | Fluticasone (4.2 %) | ||||
Ciclesonide (1.0 %) | ||||||
Sex hormones and modulators of the genital system (NW: 46830) (ND: 84543) | Medroxyprogesterone (10.9 %)a | Oestradiol (0.9 %) (estrogen) | Levonorgestrel with ethinyloestradiol (56.3 %)a | Norethisterone (3.4 %) (N = 3504)b | ||
Etonogestrel (19.3 %)a | Medroxyprogesterone (1.1 %) (N = 1001)b | |||||
Norethisterone with ethinyloestradiol (5.5 %)a | ||||||
Levonorgestrel (4.4 %)a | ||||||
Norethisterone (1.1 %)a | ||||||
Clomiphene (0.6 %) (ovulation stimulant) | ||||||
Drugs for acid-related disorders (NW: 19444) (ND: 59365) | Rabeprazole (9.8 %) | Esomeprazole (56.4 %) | ||||
Ranitidine (7.2 %) | Pantoprazole (16.4 %) | |||||
Esomeprazole and amoxicilan and clarithromycin (9.2 %) | ||||||
Omeprazole (6.6 %) | ||||||
Lansoprazole (1.2 %) | ||||||
Nizatidine (0.7 %) | ||||||
Antiepileptics (NW: 7784) (ND: 46092) | Gabapentin (1.9 %) | Pregabalin (29.0 %) | Clonazepam (1.9 %) | Valproate (29.1 %) (N = 8364) | ||
Levetiracetam (7.8 %) | Topiramate (14.3 %) (N = 7607) | |||||
Lacosamide (1.0 %) | Lamotrigine (11.6 %) (N = 8803 | |||||
Carbamazepine (10.5 %) (N = 3153) | ||||||
Phenytoin (1.3 %) (N = 472) | ||||||
Oxcarbazepine (0.7 %) (N = 410) | ||||||
Anti-inflammatory products (NW: 14676) (ND: 25747) | Celecoxib (13.9 %) | Ibuprofen (23.7 %) | ||||
Diclofenac (21.1 %) | ||||||
Meloxicam (20.6 %) | ||||||
Naproxen (13.1 %) | ||||||
Mefenamic acid (10.6 %) | ||||||
Indomethacin (3.9 %) | ||||||
Piroxicam (1.5 %) | ||||||
Corticosteroids, dermatological preparations (NW: 14759) (ND: 23389) | Mometasone (37.7 %) | |||||
Betamethasone (34.7 %) | ||||||
Methylprednisolone (21.3 %) | ||||||
Hydrocortisone (13.4 %) | ||||||
Triamcinolone (8.4 %) | ||||||
Drugs used in diabetes (NW: 6792) (ND: 21668) | Insulin aspart (23.8 %) | Insulin glargine (16.0 %) | Metformin (40.4 %) | |||
Insulin (human) (8.7 %) | Sitagliptin (1.8 %) | Gliclazide (5.5 %) | ||||
Insulin lispro (5.7 %) | Metformin with sitagliptin (3.0 %) | |||||
Insulin detemir (5.6 %) | Exenatide (1.9 %) | |||||
Insulin aspart/protamine (3.3 %) | Metformin with vildagliptin (1.4 %) | |||||
Lipid modifying agents (NW: 3842) (ND: 20916) | Fenofibrate (5.6 %) | Rosuvastatin (45.3 %) (N = 9225) | ||||
Ezetimibe (3.7 %) | Atorvastatin (39.3 %) (N-7760) | |||||
Simvastatin (4.0 %) (N = 750) | ||||||
Simvastatin and ezetimibe (3.1 %) (N = 680) | ||||||
Atorvastatin and amlodipine (2.3 %) (N = 544) | ||||||
Agents acting on renin-angiotensin system (NW: 3560) (ND: 19330) | Perindopril (29.7 %) (N = 5191) | |||||
Candesartan (12.8 %) (N = 2154) | ||||||
Irbesartan (12.2 %) (N = 2349) | ||||||
Telmisartan (12.1 %) (N = 2183) | ||||||
Ramipril (10.6 %) (N = 2030) | ||||||
Perindopril and amlodipine (7.4 %) (N = 1412) | ||||||
Olmesartan (5.8 %) (N = 949) | ||||||
Irbesartan with hydrochlorothiazide (HCTZ) (5.1 %) (N = 866) | ||||||
Perindopril with indapamide (4.4 %) (N = 789) | ||||||
Telmisartan with HCTZ (4.2 %) (N = 722) | ||||||
Candesartan with HCTZ (4.2 %) (N = 685) | ||||||
Antivirals for systemic use (NW: 6837) (ND: 16556) | Famciclovir (32.6 %) | Valaciclovir (60.2 %) | ||||
Aciclovir (8.1 %) | ||||||
Drugs for gastrointestinal disorders (NW: 8874) (ND: 13074) | Metoclopramide (88.6 %) | Domperidone (11.4 %) |